Compare · AXGN vs CNMD
AXGN vs CNMD
Side-by-side comparison of Axogen Inc. (AXGN) and CONMED Corporation (CNMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGN and CNMD operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- AXGN is the larger of the two at $2.06B, about 1.5x CNMD ($1.35B).
- AXGN has been more active in the news (6 items in the past 4 weeks vs 1 for CNMD).
- CNMD has more recent analyst coverage (16 ratings vs 11 for AXGN).
- Company
- Axogen Inc.
- CONMED Corporation
- Price
- $35.20-1.18%
- $47.08-0.14%
- Market cap
- $2.06B
- $1.35B
- 1M return
- -22.26%
- -
- 1Y return
- +109.90%
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 1987
- News (4w)
- 6
- 1
- Recent ratings
- 11
- 16
Axogen Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
CONMED Corporation
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. It offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Latest AXGN
- Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
- BofA Securities initiated coverage on AxoGen with a new price target
- Barclays initiated coverage on AxoGen with a new price target
- Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week
- Axogen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
- SEC Form 424B5 filed by Axogen Inc.
- Amendment: Axogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
Latest CNMD
- CONMED Corporation to Report Third Quarter 2026 Financial Results on October 28, 2026
- Director Kelderman Kim converted options into 500 shares (SEC Form 4)
- CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference
- SEC Form 10-Q filed by CONMED Corporation
- CONMED Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- CONMED Corporation Reports Second Quarter 2026 Financial Results; Updates Full Year 2026 Guidance
- CONMED Corporation Announces Expanded Indication for the FDA Cleared AirSeal® Robotic Solution for Use with the Intuitive da Vinci 5 Hex Cannula
- CONMED Corporation to Participate in the Society of Robotic Surgery Annual Meeting
- SEC Form 4 filed by Executive Vice President & CFO Gallagher John E
- New insider Gallagher John E claimed no ownership of stock in the company (SEC Form 3)